Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Top Cited Papers
Open Access
- 1 May 2006
- journal article
- review article
- Published by Elsevier in American Journal of Transplantation
- Vol. 6 (5) , 859-866
- https://doi.org/10.1111/j.1600-6143.2006.01288.x
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndromePediatric Nephrology, 2005
- Humoral Theory of Transplantation: Mechanism, Prevention, and TreatmentHuman Immunology, 2005
- Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTransplant Immunology, 2003
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- No clinical evidence for CD4+ cell depletion caused by rituximabBlood, 2003
- Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the Lung of a 10-Year-Old GirlPediatric Hematology and Oncology, 2003
- Maintenance of Serological Memory by Polyclonal Activation of Human Memory B CellsScience, 2002
- Rituximab and other emerging monoclonal antibody therapies for lymphomaEmerging Drugs, 2002
- Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)Clinical Immunology, 2001
- Humoral Transplantation Antibodies Play a Role in Protracted Rejection of Murine Renal AllograftsInternational Archives of Allergy and Immunology, 1991